Compare VanEck Gold Miners ETF (GDX) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Gold Miners ETF vs Illumina, Inc. — how do they compare? VanEck Gold Miners ETF trades at $72.04, while Illumina, Inc. trades at $189.22 (market cap $28.32B). The key difference: Illumina, Inc. is trading nearer its 52-week high, VanEck Gold Miners ETF nearer its low. Which is the better fit depends on your goals.
| GDX | ILMN | |
|---|---|---|
52-Week High | $115.84 | $194.33 |
52-Week Low | $51.15 | $91.00 |
Market Cap | — | $28.32B |
Sector | — | Health |
Enterprise Value | — | $29.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The VanEck Gold Miners ETF (GDX) is trading at $71.97, down 3.89% over the past 24 hours, with a strong bearish technical signal from moving averages. The fund provides exposure to senior gold mining equities, which are currently trading at historically low valuations according to recent analysis, with forward P/E and EV/EBITDA multiples at five-year lows. Recent news highlights ongoing comparisons with lower-fee bullion ETFs and debates about the optimal vehicle for gold exposure.
The outlook presents a dichotomy: attractive valuation metrics and record free cash flow yields suggest potential upside if gold prices rally, while technical weakness and competition from more efficient gold ETFs pose significant risks. A re-rating to historical valuation norms could imply 20% upside, but the fund's performance remains heavily dependent on gold price movements and mining company operational execution.
Illumina (ILMN) trades at $191.20, up 0.61% with strong technical momentum near 52-week highs. The company shows robust fundamentals with consistent earnings beats, 19.42% net margin, and improving cash flow. Recent leadership appointments and product launches support growth narrative. Technical indicators show bullish momentum with support at $188 and resistance at $194.
Outlook remains positive with strong sequencing demand and margin expansion driving recovery. Risks include competition from Roche's new sequencer and China market weakness. Analyst consensus is bullish with 51% buy ratings but price target of $174.44 suggests limited upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Gold Miners ETF
The fund normally invests at least 80% of its total assets in common stocks and depositary receipts of companies involved in the gold mining industry. The index is a modified market-capitalization weighted index primarily comprised of publicly traded companies involved in the mining for gold and silver. The fund is non-diversified.
Read more on GDX →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
